| CEO Name | Christophe Weber |
| Nationality | France |
| Net Worth Estimation | $30 million |
Christophe Weber's estimated net worth of approximately $30 million USD reflects accumulated executive compensation, stock awards, and performance bonuses received during his tenure as CEO of Takeda Pharmaceutical Company Limited. Public filings and financial disclosures attribute much of this value to his leadership since 2015 and stock appreciation from Takeda's global expansion.
Christophe Weber's estimated net worth of $30,000,000 is 28.6% of the maximum CEO net worth in the healthcare category and triple the minimum threshold. His wealth places him in the mid-range among healthcare CEOs between $10,000,000 and $90,000,000.
Business Category: Healthcare
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD
Christophe Weber Performance in Takeda Pharmaceutical Company Limited
Christophe Weber, CEO of Takeda Pharmaceutical Company Limited, demonstrates strategic leadership by driving innovation and global expansion. His decision-making emphasizes R&D investment and acquisitions, notably the Shire acquisition, enhancing Takeda's pipeline and market position. Under his guidance, Takeda has improved financial performance and operational efficiency, solidifying its status as a leading biopharmaceutical firm.
Latest News
Takeda Pharmaceutical Company Limited CEO Transition and Strategic Updates in 2025
Takeda's CEO Christophe Weber announced his planned retirement in June 2026, to be succeeded by Julie Kim, currently president of Takeda's U.S. Business Unit. Takeda is focusing on pipeline growth with regulatory filings for new drugs, strategic partnerships in oncology, and exiting its cell therapy platform amid a structural realignment to enhance profitability and long-term innovation.
Source: http://www.takeda.com/newsroom/newsreleases/2025/julie-kim-appointed-successor-ceo/